Codexis (CDXS) Scheduled to Post Quarterly Earnings on Thursday

Codexis (NASDAQ:CDXS) is set to release its earnings data after the market closes on Thursday, May 2nd. Analysts expect Codexis to post earnings of ($0.17) per share for the quarter. Codexis has set its FY 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.18. Codexis had a negative net margin of 108.69% and a negative return on equity of 47.58%. The business had revenue of $26.56 million for the quarter, compared to the consensus estimate of $24.73 million. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Stock Performance

Shares of NASDAQ CDXS opened at $2.80 on Thursday. The firm has a market cap of $196.84 million, a P/E ratio of -2.52 and a beta of 2.01. Codexis has a 1 year low of $1.45 and a 1 year high of $4.91. The firm’s 50 day moving average price is $3.32 and its 200 day moving average price is $2.72.

Analyst Ratings Changes

Several research firms have recently issued reports on CDXS. StockNews.com upgraded Codexis to a “sell” rating in a report on Tuesday, March 5th. Benchmark raised Codexis from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research note on Thursday, February 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.80.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.